The European Medicines Agency's Committee for Veterinary Medicinal Products (CVMP) is scheduled to meet from 14 to 16 July 2026 to review several marketing authorisation applications and variations, according to the agenda published on 10 July 2026. The meeting, chaired by G. J. Schefferlie with vice-chair F. Hasslung Wikström, will take place in Room 2C and virtually.
Among the items for opinion is bexagliflozin (EMEA/V/C/006300/0000) for cats, a new active substance for veterinary use. The committee will also address outstanding issues for buprenorphine hydrochloride (EMEA/V/C/006749/0000) for cats, dogs, and horses, as well as a combination product of lotilaner, moxidectin, pyrantel, and praziquantel (EMEA/V/C/006753/0000) for dogs. Other products under review include a porcine circovirus type 2d vaccine (EMEA/V/C/006873/0000) for pigs, canine adipose-derived mesenchymal stem cells (EMEA/V/C/006457/0000) for dogs, and a Streptococcus suis vaccine (EMEA/V/C/006952/0000) for pigs.
The agenda also includes a re-examination of the CVMP opinion on Scovella (velagliflozin, EMEA/V/C/006610/0000) for horses. In the variations section, the committee will consider opinions for Mometamax Ultra (gentamicin/posaconazole/mometasone furoate) and Cimalgex (cimicoxib) for dogs, and address outstanding issues for Upcard (torasemide) for dogs and Prevomax (maropitant) for dogs and cats.
The meeting will also cover maximum residue limits (MRLs), with one list of questions (EMEA/V/MRL/007033/FULL/0001) on the agenda. No prior coverage of this meeting exists in recent months.
The CVMP is responsible for evaluating veterinary medicines and establishing MRLs for pharmacologically active substances used in food-producing animals. The outcomes of these procedures will be published in the CVMP meeting highlights once finalised. Stakeholders impacted include veterinary pharmaceutical companies seeking EU-wide marketing authorisations, veterinarians and animal owners who will gain access to new treatments, and regulators in EU member states who will implement the committee's decisions. The meeting's decisions could affect the availability of treatments for common conditions in companion animals and livestock, with potential benefits for animal health and welfare, while also imposing compliance costs on manufacturers.